A Commentary on the Role of Pulmonary Function Parameters in Idiopathic Pulmonary Fibrosis Follow-Up.
作者信息
Degirmenci Guliz, Satici Celal
机构信息
Department of Pulmonology, Health Science University, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.
出版信息
Clin Respir J. 2024 Jun;18(6):e13797. doi: 10.1111/crj.13797.
Abstract
摘要
相似文献
1
A Commentary on the Role of Pulmonary Function Parameters in Idiopathic Pulmonary Fibrosis Follow-Up.肺功能参数在特发性肺纤维化随访中的作用述评
Clin Respir J. 2024 Jun;18(6):e13797. doi: 10.1111/crj.13797.
2
Airway Microstructure in Idiopathic Pulmonary Fibrosis: Assessment at Hyperpolarized He Diffusion-weighted MRI.特发性肺纤维化的气道微观结构：超极化氦扩散加权 MRI 的评估。
Radiology. 2019 Apr;291(1):223-229. doi: 10.1148/radiol.2019181714. Epub 2019 Feb 19.
3
Efficacy of TCM therapy of tonifying lung-kidney's Qi-deficiency in a case of idiopathic pulmonary fibrosis: A case report.中医补益肺肾气虚疗法治疗特发性肺纤维化 1 例的疗效：病例报告
Medicine (Baltimore). 2019 May;98(18):e15140. doi: 10.1097/MD.0000000000015140.
4
Influence of radiological emphysema on lung function test in idiopathic pulmonary fibrosis.放射性肺气肿对特发性肺纤维化肺功能检查的影响。
Respir Med. 2013 Nov;107(11):1781-8. doi: 10.1016/j.rmed.2013.08.039. Epub 2013 Sep 3.
5
Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.单中心真实世界经验：吡非尼酮治疗特发性肺纤维化和特发性非特异性间质性肺炎纤维化患者的疗效。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963015. doi: 10.1177/1753466620963015.
6
Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis.肺气肿对特发性肺纤维化肺功能的生理和预后特征的影响。
Respirology. 2019 Jan;24(1):55-62. doi: 10.1111/resp.13387. Epub 2018 Aug 23.
7
Autoantibody status is not associated with change in lung function or survival in patients with idiopathic pulmonary fibrosis.自身抗体状态与特发性肺纤维化患者的肺功能变化或生存无关。
Respir Med. 2019 Jul;153:85-90. doi: 10.1016/j.rmed.2019.05.019. Epub 2019 May 29.
8
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.吡非尼酮治疗特发性肺纤维化伴更严重肺功能损害的患者。
Respir Med. 2019 Jul;153:44-51. doi: 10.1016/j.rmed.2019.04.016. Epub 2019 Apr 24.
9
Idiopathic Pulmonary Fibrosis: Data-driven Textural Analysis of Extent of Fibrosis at Baseline and 15-Month Follow-up.特发性肺纤维化：基于数据的基线和15个月随访时纤维化范围的纹理分析
Radiology. 2017 Oct;285(1):270-278. doi: 10.1148/radiol.2017161177. Epub 2017 May 10.
10
Serial 6-month change in forced vital capacity predicts subsequent decline and mortality in Japanese patients with newly diagnosed idiopathic pulmonary fibrosis.新诊断特发性肺纤维化日本患者用力肺活量的 6 个月连续变化可预测随后的下降和死亡率。
Respir Investig. 2021 May;59(3):335-341. doi: 10.1016/j.resinv.2020.12.008. Epub 2021 Feb 4.
本文引用的文献
1
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.特发性肺纤维化（更新版）和成人进展性肺纤维化：美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会临床实践指南。
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST.
2
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis.用力肺活量下降率预处理预测特发性肺纤维化患者对吡非尼酮的长期反应。
Sci Rep. 2018 Apr 13;8(1):5961. doi: 10.1038/s41598-018-24303-4.
3
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.尼达尼布治疗特发性肺纤维化患者的长期疗效：来自 TOMORROW 试验及其开放标签扩展研究的结果。
Thorax. 2018 Jun;73(6):581-583. doi: 10.1136/thoraxjnl-2016-209701. Epub 2017 Oct 9.
4
EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.EMPIRE 注册研究，捷克部分：人口统计学、肺功能和高分辨率计算机断层扫描对特发性肺纤维化患者生存及临床病程的影响
Clin Respir J. 2018 Apr;12(4):1526-1535. doi: 10.1111/crj.12700. Epub 2017 Sep 26.
5
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化患者的 3 期临床试验。
N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18.
6
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.尼达尼布治疗特发性肺纤维化的疗效和安全性。
N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18.
7
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.吡非尼酮治疗特发性肺纤维化（CAPACITY）患者的两项随机试验。
Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13.
Zotero 插件